| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.2 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.2 |